Development and assessment of 153Sm-zoledronate complex as a possible bone pain palliative agent

Authors

  • Amir Reza Jalilian Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran|Radioisotope Products and Radiation Technology Section, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria
  • Hamid Golchoobian Department of Inorganic Chemistry, University of Mazandaran, Babolsar, Iran
  • Masood Arabieh Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
  • Mirsaeed Nikzad Department of Inorganic Chemistry, University of Mazandaran, Babolsar, Iran
  • Saeed Shanesazzadeh Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Abstract:

Introduction:In this work, 153Sm-zoledronate (153Sm-ZLD) was studied using computational chemistry methods and prepared for possible use in bone pain palliation therapy. Methods: The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state using computational chemistry methods followed by 153Sm-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in animals were studied and used for absorbed dose determination in critical organs. Results: The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state and computational chemistry methods showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. 153Sm-ZLD complex was prepared with >99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with >95% binding to HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs. Conclusion: The 153Sm-ZLD complex data were compared to 153Sm-EDTMP and 153Sm-BPAMD.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Development of 166Ho-zoledronate as a bone marrow ablative agent

In this study, production, quality control and biodistribution studies of 166Ho-zoledronate have been presented as a possible bone marrow ablative agent. Ho-166 chloride was produced by thermal neutron irradiation of natural 165Ho(NO3)3 samples. 166Ho-zoledronate complex was prepared by adding the desired amount of zoledronate solution (0.2 mL, 150 mg/ml in 1 M NaOH) to appropriate amount of th...

full text

Development of 153Sm/177Lu-EDTMP as a possible therapeutic complex

Introduction:Targeted radionuclide therapy (TRT) has been demonstrated to be an effective therapeutic tool in patients with disseminated bone metastasis. TRT is generally performed with a single radionuclide. In this study we investigated the feasibility of combined TRT with a high-energy beta emitter (153Sm) and a low energy beta emitter (177Lu) in wistar...

full text

Production, quality control and biological evaluation of 153Sm-TTHMP as a possible bone palliation agent

Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: 153Sm-TTHMP was prepared starting from 153<...

full text

Preparation of a 153Sm-5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin complex as a possible therapeutic agent

Introduction: Porphyrins are interesting derivatives with low toxicity, tumor avidity and rapid wash-out suggested as potential radiopharmaceuticals in radiolabeled form. In this work we report, synthesis, radiolabeling, quality control, stability, partition coefficient determination and biodistribution studies of 153Sm-5,10,15,20-tetrakis(4-methoxyphenyl) porphyrin (153Sm-4-MPP) in ...

full text

development of 166ho-zoledronate as a bone marrow ablative agent

in this study, production, quality control and biodistribution studies of 166ho-zoledronate have been presented as a possible bone marrow ablative agent. ho-166 chloride was produced by thermal neutron irradiation of natural 165ho(no3)3 samples. 166ho-zoledronate complex was prepared by adding the desired amount of zoledronate solution (0.2 ml, 150 mg/ml in 1 m naoh) to appropriate amount of th...

full text

development of 153sm/177lu-edtmp as a possible therapeutic complex

introduction:targeted radionuclide therapy (trt) has been demonstrated to be an effective therapeutic tool in patients with disseminated bone metastasis. trt is generally performed with a single radionuclide. in this study we investigated the feasibility of combined trt with a high-energy beta emitter (153sm) and a low energy beta emitter (177lu) in wistar rats. methods: the cocktail complex of...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 25  issue 2

pages  81- 91

publication date 2017-07-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023